Readoutin 14d
Vanda Pharmaceuticals — VQW-765
Phase 3 primary completion: Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorder.
- Date
- Dec 2026
- Type
- Readout
- Indication
- Social Anxiety Disorder (SAD)